First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome, ...
COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback